A Post-authorization Study to Describe the Safety and Efficacy of Emapalumab for the Treatment of pHLH in Treatment Experienced Chinese Patients

NCT05744063 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

13

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Hemophagocytic Lymphohistiocytosis

Interventions

DRUG: Emapalumab-Lzsg 5 MG/ML [Gamifant]

Sponsor

Swedish Orphan Biovitrum